From Talent to Success: Axi Select Announces Fourth Pro M Trader, Now Managing $1 Million USD of Axi Funds
This breakthrough reflects the broker's ongoing commitment to empower ambitious and talented traders through a program that is designed to unlock and maximise their full trading and profit potential.
Louis Cooper, Chief Commercial Officer at Axi, shares his excitement for the program's latest success, noting ' We're proud to see our program continue to elevate traders, helping them trade and improve their trading skills all the way to the top. Since launching Axi Select in 2023, we've been confident in its ability to harness the talent of all traders to new heights – regardless of gender or experience level. Today, we celebrate a landmark moment: our fourth Pro M trader and the first woman to reach the program's top stage and secure a $1M allocation. Ms. Looi demonstrated outstanding skill, talent, and discipline – and with the right tools and support, she now manages $1M of Axi funds. '
A few months ago, Axi Select announced its first three $1M funded traders: Francisco Quesada Godines, Daniel Gutiérrez Viñas, and 21-year-old trader, Kayan Freitas. The program offers traders the opportunity to access capital funding up to $1,000,000 USD and earn up to 90% of their profits, as well as the advantage to join the program with zero registration or monthly fees*. Moreover, Axi Select uses a Standard or a Pro live account, unrestrictive trading conditions, an exclusive trading room, and more. Recently, the broker was recognised with the 'Best Funded Trader Programme' award by the ADVFN International Financial Awards, and, among others, was honoured by Finance Feeds with the 'Most Innovative Proprietary Trading Firm' award.
The Axi Select program is only available to clients of AxiTrader Limited. CFDs carry a high risk of investment loss. In our dealings with you, we will act as a principal counterparty to all of your positions. This content is not available to AU, NZ, EU and UK residents. For more information, refer to our Terms of Service. *Standard trading fees apply.
Watch announcement video here.
About Axi
Axi is a global online FX and CFD trading company, with thousands of customers in 100+ countries worldwide. Axi offers CFDs for several asset classes including Forex, Shares, Gold, Oil, Coffee, and more.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
37 minutes ago
- Globe and Mail
DDC Enterprise Appoints Seasoned Investment Executive Kyu Ho as Chief of Staff and Launches Advisory Councils to Expand Bitcoin Treasury Leadership Team
DDC Enterprise Limited (NYSE: DDC) ('DDC' or the 'Company'), a publicly listed Asian food and digital asset platform, today announced the appointment of Kyu Ho as Chief of Staff, further strengthening its executive leadership team. This press release features multimedia. View the full release here: Executive Appointment: Kyu Ho Named Chief of Staff Kyu Ho joins DDC with over two decades of experience spanning traditional finance and digital assets investing. He is the Co-Founder and Managing Partner at Initial Ventures, an early-stage crypto investment firm, and formerly led Thematic Investing in Asia at the CPP Investments, a C$700 billion Canadian Pension Fund. He has held senior investment and management roles at hedge funds including Kingdon Capital and Value Partners, and was the Founder and CIO of Wuzhu Asia Partners. Kyu received a Bachelor of Arts in Economics from Northwestern University, a Master of Business Administration from The Wharton School at University of Pennsylvania. In his role as Chief of Staff, Kyu will oversee the formation and execution of the Company's Bitcoin accumulation strategy, treasury yield optimization, institutional grade custodian network management, and cross-functional alignment as DDC rapidly scales its Bitcoin treasury. Kyu has been a strategic advisor to DDC since earlier this year. 'One of the differentiating assets to DDC's approach is our A-list senior executive team with in-depth experience across both tradfi and crypto. On top of that, we surround our management team with a Bitcoin-centric strategic advisory network,' said Norma Chu, Founder, Chairwoman, and CEO of DDC. 'Kyu's unique cross-sector expertise and conviction in Bitcoin make him an essential addition to the top management at DDC as we continue our laser focused-execution.' DDC's Recent Launch of Bitcoin Visionary Council and Bitcoin Influence Collective DDC has launched the Bitcoin Visionary Council ('BVC') — a strategic advisory body designed to ensure the company's Bitcoin treasury operations align with cutting-edge industry standards and long-term value creation. Yat Siu, Co-Founder and Executive Chairman of Animoca Brands, has been appointed as the inaugural member of the Council. A pioneer in digital property rights and the open metaverse, Yat is globally recognized for building infrastructure at the intersection of finance, gaming, and Web3. His appointment brings deep vision and institutional credibility to the Council as it shapes DDC's Bitcoin strategy for the future. Complementing this institutional leadership, DDC also announced the Bitcoin Influence Collective ('BIC') — a mission-driven advisory group of key thought leaders and seasoned Bitcoin investors focused on contributing to the company's strategic directions and industry-specific innovations. Its four founding members include Adrian Morris, Lemar Ashhar, Magdalena Gronowska, and Tim Kotzman. These new leadership and advisory additions reflect DDC's commitment to executing one of the most forward-thinking and disciplined Bitcoin strategies among public companies globally. About DDC Enterprise Limited DDC Enterprise Limited (NYSE: DDC) is spearheading the corporate Bitcoin treasury revolution while maintaining its foundation as a leading global Asian food platform. The Company has strategically positioned Bitcoin as a core reserve asset, executing a bold and accelerating accumulation strategy. While continuing to grow its portfolio of culinary brands – including DayDayCook, Nona Lim, and Yai's Thai – DDC is now at the vanguard of public companies integrating Bitcoin into their financial architecture.
National Post
an hour ago
- National Post
LTIMindtree Delivers an All-Round USD Growth of 2% QoQ
Article content Q1 PAT up 12.6% QoQ; Order Book at $1.6Bn, up 17% YoY Article content MUMBAI, India — LTIMindtree [NSE: LTIM, BSE: 540005], a global technology consulting and digital solutions company, announced its consolidated results today for the first quarter ended June 30, 2025, as approved by its Board of Directors. Article content 'We had a promising start to the year delivering broad-based growth, expanding margins, and making significant progress on our strategic priorities. Our Fit4Future program, sales transformation efforts, and pivot to AI have enhanced agility and strengthened our ability to scale for the future. While the macroeconomic environment remains challenging, I'm confident that our disciplined execution and unwavering client focus will continue to drive our performance.' Article content – Article content Venu Lambu, Chief Executive Officer and Managing Director Article content Key financial highlights: Article content Quarter ended June 30, 2025 Article content In USD: – Revenue at $1,153.3 million (+2.0% Q-o-Q / +5.2% Y-o-Y) – Operating Margin (EBIT) at 14.3%, expands by 50 bps Q-o-Q – Net profit at $147.0 million (+12.6% Q-o-Q / +8.0% Y-o-Y) In INR: – Revenue at Rs. 98,406 million (+0.7% Q-o-Q / +7.6% Y-o-Y) – Net profit at Rs. 12,546 million (+11.2% Q-o-Q / +10.5% Y-o-Y) Article content Other highlights: Article content Clients: – 741 active clients as of June 30, 2025 – $1 million+ clients increased by 14 on a Y-o-Y basis, total 404 – $5 million+ clients increased by 11 on a Y-o-Y basis, total 159 – $10 million+ clients increased by 3 on a Y-o-Y basis, total 90 – $50 million+ clients increased by 2 on a Y-o-Y basis, total 14 Article content People: Article content – 83,889 professionals as of June 30, 2025 – Trailing 12-month attrition was 14.4% – Utilization (ex-trainees) at 88.1% Article content Deal Wins Article content A global agribusiness leader selected LTIMindtree to implement an AI-driven model for application management, infrastructure support, and cybersecurity services. This suite of IT services includes SAP S/4HANA, ServiceNow, Microsoft Azure, and AI frameworks and focuses on efficiency and growth, driven by vendor consolidation. A global leader in professional services has chosen LTIMindtree as part of their supplier consolidation initiative spanning Client Technology, Enterprise Technology, and Information Security. A major European financial institution chose LTIMindtree as its long-term transformation partner to migrate from a legacy system to a flagship Transaction Processing Platform, integrating Gen AI and automation in the solution to accelerate delivery. Selected as a strategic partner by a leading digital company in the Middle East to manage their supply chain and digital landscape. A major utility company has engaged LTIMindtree to support the management and integration of applications across multiple ERP systems. A foreign government organisation has entrusted LTIMindtree with implementing a digital transformation initiative to overhaul its tax system and modernize the tax administration process. A leading recycling organisation in the Nordics has chosen LTIMindtree for a Managed service deal. A leading US-based Oil & Gas major has entrusted LTIMindtree with a multi-delivery contract to cater across Cloud, Data, SAP, and AI services. Article content Partnerships Article content LTIMindtree was honored with the 'Diversity in Security' award at the 2025 Microsoft Security Excellence Awards event, organized by the MISA. This award emphasizes the company's dedication to promoting inclusive security teams and providing innovative security solutions seamlessly integrated with Microsoft technology for clients around the world. LTIMindtree was honored to be named 'Google Partner of the Year 2025 for Industry Solutions in Manufacturing' for the second year in a row. LTIMindtree has been named a premier partner for AWS's RAPID GenAI assessment program. The program covers use case validation, data security, performance testing, migration, and integration, enabling faster deployment and co-investment in pre-sales. LTIMindtree has been named the '2025 Databricks Business Transformation Partner' of the Year. Presented at the annual Data + AI Summit, the award highlights LTIM's exceptional contributions to driving data and AI-led transformation across industries. LTIMindtree is recognized as the 'FY25 India Partner of the Year' by Boomi. As a valued Boomi partner, LTIMindtree has been instrumental in assisting joint customers in optimizing their business operations through Agentic AI, intelligent connectivity, and automation solutions. At the annual Snowflake Summit 2025, LTIMindtree was honored with the 'Manufacturing & Industrials Data Cloud Services Partner of the Year' award by Snowflake, the AI Data Cloud company. Article content Recognitions Article content LTIMindtree positioned as a Leader in ISG's Provider Lens™ SAP Ecosystem 2025 for 'RISE with SAP Implementation' and 'SAP Business AI & BTP services' globally. LTIMindtree positioned as a Leader in ISG's Provider Lens™ Evaluation for Duck Creek Services Ecosystem 2025. LTIMindtree recognized as a Leader in HFS Horizons: Energy & Utilities Service Providers, 2025. LTIMindtree recognized as a Leader in Everest Group: Talent Readiness for Next-Gen Application Services PEAK Matrix® Assessment 2025. LTIMindtree recognized as Major Contenders in Everest Group: Microsoft Modern Work Services PEAK Matrix® Assessment 2025. LTIMindtree recognized as Major Contenders in Everest Group: Intelligent Process Automation Solutions PEAK Matrix® Assessment 2025. LTIMindtree recognized as Major Contenders in Everest Group: Life Sciences Enterprise Platform Services PEAK Matrix® Assessment 2025. LTIMindtree recognized as Major Contenders in Everest Group: Healthcare Data, Analytics and AI Services PEAK Matrix® Assessment 2025. LTIMindtree recognized as Major Contenders in Everest Group: Life Sciences Digital Services PEAK Matrix® Assessment 2025. LTIMindtree recognized as a Disruptor in HFS Horizons: Insurance Services, 2025. Article content About LTIMindtree Article content LTIMindtree is a global technology consulting and digital solutions company that enables enterprises across industries to reimagine business models, accelerate innovation, and maximize growth by harnessing digital technologies. As a digital transformation partner to more than 700 clients, LTIMindtree brings extensive domain and technology expertise to help drive superior competitive differentiation, customer experiences, and business outcomes in a converging world. Powered by 83,000+ talented and entrepreneurial professionals across more than 40 countries, LTIMindtree — a Larsen & Toubro Group company — solves the most complex business challenges and delivers transformation at scale. For more information, please visit Article content Article content Article content Article content Article content
National Post
2 hours ago
- National Post
Cybin Receives UK MHRA Approval to Commence EMBRACE, A Multinational Pivotal Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder
Article content Article content the United States, Europe and Australia and will commence imminently – Article content – PARADIGM TM comprises two 12-week randomized, double-blind, placebo-controlled studies (APPROACH® and EMBRACE®) and a long-term extension study (EXTEND), with anticipated combined enrollment of approximately 550 participants – Article content – Dosing is currently underway in the first pivotal study, APPROACH, and patient rollover has begun into EXTEND – Article content TORONTO — Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (' Cybin ' or the ' Company '), a clinical-stage breakthrough neuropsychiatry company committed to advancing mental healthcare by developing new and innovative next-generation treatment options, today announced that it has received approval from the UK Medical and Healthcare Products Regulatory Agency ('MHRA') to commence EMBRACE, the second pivotal study in PARADIGM, the Company's Phase 3 multinational program evaluating CYB003, a proprietary deuterated psilocin analog. The Company previously received Breakthrough Therapy Designation from the U.S. Food and Drug Administration ('FDA') for CYB003 for the adjunctive treatment of Major Depressive Disorder ('MDD'). Article content 'MHRA approval to initiate the EMBRACE component of our PARADIGM program in the UK marks an important step forward as we advance our lead program, CYB003, through the regulatory process,' said Doug Drysdale, Chief Executive Officer of Cybin. 'The Agency's decision serves as strong validation of both the quality of our data and the urgent need to develop new and effective therapeutics to treat depression. With expected enrollment of 330 participants suffering from moderate to severe MDD, the EMBRACE study aims to generate critical late-stage data that, ultimately, may lead to transforming the standard of care for patients in need.' Article content 'There are encouraging signs of clinical and commercial success across this sector, along with increasing political and regulatory support. Health expert Dr. Martin Makary, Commissioner of the U.S Food and Drug Administration, has publicly recognized the potential value of these innovative therapeutics and has stated his intention to prioritize and expedite the review process. The commercial success of esketamine is also a positive signal for the entire sector. In the second quarter of 2025, esketamine sales totaled $366 million in the U.S. and $414 million worldwide, representing 61.1% growth year over year in the U.S., and an annual run rate of roughly $1.7 billion. 1 These positive factors contribute to the credibility and opportunity of the work we are doing at Cybin,' concluded Drysdale. Article content Study Design: Article content EMBRACE will enroll 330 patients suffering from moderate to severe MDD (MADRS≥24) who are on a stable dose of antidepressant medication but are responding inadequately. Study participants will be randomized 1:1:1 to receive either CYB003 16 mg, CYB003 8 mg, or inactive placebo. Each study arm will evaluate two doses, administered three weeks apart. The primary endpoint will be change in depressive symptoms as measured by change in MADRS from baseline at six weeks after the first dose. Article content EMBRACE is the second Phase 3 randomized, double-blind clinical trial in the PARADIGM program, and is expected to enroll participants at approximately 60 clinical sites across the U.S., Europe, and Australia. The first Phase 3 trial, APPROACH, is taking place at approximately 45 clinical sites across the U.S. Participants from APPROACH and EMBRACE will have the opportunity to roll over into EXTEND after completing the 12-week, double-blind, placebo-controlled treatment periods. Sources Article content Cybin is a late-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options to address the large unmet need for people who suffer from mental health conditions. Article content With promising proof-of-concept data, Cybin is working to change the mental health treatment landscape through the introduction of intermittent treatments that provide long lasting results. The Company is currently developing CYB003, a proprietary deuterated psilocin analog, in Phase 3 studies for the adjunctive treatment of major depressive disorder and CYB004, a proprietary deuterated N, N-dimethyltryptamine molecule in a Phase 2 study for generalized anxiety disorder. The Company also has a research pipeline of investigational, 5-HT-receptor focused compounds. Founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom, the Netherlands and Ireland. For Company updates and to learn more about Cybin, visit or follow the team on X, LinkedIn, YouTube and Instagram. Article content Cautionary Notes and Forward-Looking Statements Article content Certain statements in this news release relating to the Company are forward-looking statements or forward-looking information within the meaning of applicable securities laws (collectively, 'forward-looking statements') and are prospective in nature. Forward-looking statements are not based on historical facts, but rather on current expectations and projections about future events and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. These statements generally can be identified by the use of forward-looking words such as 'may', 'should', 'could', 'potential', 'possible', 'intend', 'estimate', 'plan', 'anticipate', 'expect', 'believe' or 'continue', or the negative thereof or similar variations. Forward-looking statements in this news release include statements regarding the Company's plans to enroll participants and add additional clinical sites for the PARADIGM program; the timing of commencement of EMBRACE; the Company's plan to enroll 330 participants at 60 clinical sites across the United States, Europe and Australia for the EMBRACE study; and the Company's plans to engineer proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for mental health conditions. APPROACH and EMBRACE are registered trademarks of Cybin IRL Limited, a subsidiary of Cybin. Article content These forward-looking statements are based on reasonable assumptions and estimates of management of the Company at the time such statements were made. Actual future results may differ materially as forward-looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance, or achievements of the Company to materially differ from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such factors, among other things, include: fluctuations in general macroeconomic conditions; fluctuations in securities markets; expectations regarding the size of the psychedelics market; the ability of the Company to successfully achieve its business objectives; plans for growth; political, social and environmental uncertainties; employee relations; the presence of laws and regulations that may impose restrictions in the markets where the Company operates; implications of disease outbreaks on the Company's operations; and the risk factors set out in each of the Company's management's discussion and analysis for the year ended March 31, 2025 and the Company's annual information form for the year ended March 31, 2025, which are available under the Company's profile on SEDAR+ at and with the U.S. Securities and Exchange Commission on EDGAR at Although the forward-looking statements contained in this news release are based upon what management of the Company believes, or believed at the time, to be reasonable assumptions, the Company cannot assure shareholders that actual results will be consistent with such forward-looking statements, as there may be other factors that cause results not to be as anticipated, estimated or intended. Readers should not place undue reliance on the forward-looking statements contained in this news release. The Company assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law. Article content Cybin makes no medical, treatment or health benefit claims about Cybin's proposed products. The U.S. Food and Drug Administration, Health Canada or other similar regulatory authorities have not evaluated claims regarding psilocin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds. The efficacy of such products has not been confirmed by approved research. There is no assurance that the use of psilocin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds can diagnose, treat, cure or prevent any disease or condition. Rigorous scientific research and clinical trials are needed. If Cybin cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on Cybin's performance and operations. Article content Article content Article content Article content Contacts Article content Investor & Media Contact: Article content Article content Gabriel Fahel Article content Article content Chief Legal Officer Article content Article content Cybin Inc. Article content Article content Article content Article content
